Title
Category
Credits
Event date
Cost
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activty will discuss how precision medicine is quickly becoming a standard of care in the field of oncology and will explore recent advances in such applications as gene sequencing, molecular diagnostic assays, liquid biopsies and biomarkers. Future applications and innovations in precision medicine tailored to the treatment of specific cancers will also be examined.
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will discuss these novel agents’ indications, risks, and benefits and will address which patient populations are most likely to benefit from particular agents. In addition, early-phase clinical trials and emerging therapies will be explored.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore the most recent advances of this rapidly evolving therapy, including current data on its efficacy, limitations and challenges in the treatment of multiple myeloma and solid tumors. It will provide an overview of currently existing guidelines for CAR T-cell therapy and will describe best practices in determining individuals’ eligibility for this type of therapy, including factors that may affect treatment efficacy and outcomes.
  • Disease management
  • Health equity
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will review the impact of poorer SDOH status on cancer care, disease progression, outcomes, access to treatment and many other aspects. It will also present care models, strategies and resources to help health care professionals best confront the challenges faced by many individuals with cancer.
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This session will examine the genetic approaches being explored for these diseases, such as the introduction of a corrected or modified β-globin gene and gene-sequence editing. It will also explore the genetic modalities utilized, such as genome-editing technologies including the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene-editing system and lentiviral vectors. The safety, efficacy and challenges associated with these therapies will also be outlined.
  • Behavioral health
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will discuss the current approach for screening and management of these complications and will review data regarding the negative associations among psychological distress, health outcomes, successful HSCT, and increased mortality. Barriers in the delivery of psychosocial care and care models to address these issues will also be outlined.
  • Disease management
  • Oncology
  • Transplantation
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will provide an overview of the living-donor liver transplant procedure, the advantages and disadvantages of living-donor liver transplant, and the optimal timing for offering living donations to patients with liver cancer. Dr. Hughes will discuss the innovative approach advanced by experts at UPMC in which patients with liver cancer are offered the option of a living-donor transplant. He will discuss the experience and expertise offered by the UPMC Liver Transplant Program and their collaborative approach to working with referring physicians.
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This session discusses CAR T-cell therapy, its current trends, along with the challenges and costs, and what the future may hold for emerging treatment for various conditions.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity discusses the current prevalence trends for CRC, new insight into risk factors, recommended screening approaches and modalities, treatment updates focused on tumor-specific molecular targets, and recent and emerging findings in CRC research and clinical trials.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity aims to explore best practices in cancer screening and shed light on the groundbreaking WISDOM Study, which is revolutionizing our approach to screening by testing a personalized precision-medicine method based on individual risk factors for breast cancer in contrast to traditional annual mammograms. Participants will learn how this alternative approach differs from the current “one-size-fits-all” guideline-based method and discuss its potential to significantly improve the effectiveness of screening.

Pages